Oppenheimer Holdings delivered strong quarterly results, driven by operating leverage and a sharp rebound in capital markets, particularly ECM. Wealth management benefited from higher AUM and a favorable product mix. OPY trades at a significant valuation discount to a peer like Raymond James, with forward PE around 6.4x and annualized PE below 4x.
Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhibition offers a differentiated safety and efficacy profile versus broader PI3K inhibitors, targeting a large, underserved patient population. RLAY's $596M cash position funds operations into 2029, supporting ongoing pivotal Phase 3 and expansion studies across oncology and vascular malformations.
Oppenheimer's Brian Nagel joins 'Fast Money' to talk why he believes the slump in Nike shares could be a buying opportunity.
Amazon.com Inc (NASDAQ:AMZN) could see meaningful revenue upside over the next two years as its cloud computing arm, Amazon Web Services (AWS), continues to unlock capacity, according to Oppenheimer analysts. In a note Monday, Oppenheimer raised its price target on Amazon to $305 from $290 while reiterating an “Outperform” rating.
Telecommunications stock T-Mobile US Inc (NASDAQ:TMUS) was last seen down 1.5% to trade at $207.38, following a downgrade from Oppenheimer to "perform" from "outperform.
Oppenheimer Asset Management Inc. cut its holdings in shares of Core Laboratories Inc. (NYSE: CLB) by 9.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,951 shares of the oil and gas company's stock after selling 6,233 shares
Oppenheimer Asset Management Inc. purchased a new stake in shares of Artivion, Inc. (NYSE: AORT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,513 shares of the company's stock, valued at approximately $669,000. Oppenheimer Asset Management Inc. owned approximately 0.05% of Artivion at
Oppenheimer Asset Management Inc. raised its stake in shares of NEOS S&P 500 High Income ETF (BATS: SPYI) by 9.4% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,675 shares of the company's stock after purchasing an additional 1,086 shares during
Oppenheimer Asset Management Inc. cut its holdings in shares of CF Industries Holdings, Inc. (NYSE: CF) by 22.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,562 shares of the basic materials company's stock after selling 1,630
Oppenheimer Asset Management Inc. cut its stake in JFrog Ltd. (NASDAQ: FROG) by 7.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,248 shares of the company's stock after selling 1,195 shares during the period. Oppenheimer Asset Management
Oppenheimer Asset Management Inc. raised its position in shares of Utz Brands, Inc. (NYSE: UTZ) by 23.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,797 shares of the company's stock after acquiring an additional 7,041 shares during the quarter. Oppenheimer Asset
Oppenheimer Asset Management Inc. lifted its position in shares of McCormick and Company, Incorporated (NYSE: MKC) by 34.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,605 shares of the company's stock after acquiring an additional 1,930 shares